New! Sign up for our free email newsletter.
Science News
from research organizations

Testing investigational device for emphysema

January 27, 2015
University of Louisville
A research trial has been launched to study an investigational medical device designed to aid patients with emphysema by shutting off the diseased part of the lung.

The University of Louisville has launched a research trial to study an investigational medical device designed to aid patients with emphysema by shutting off the diseased part of the lung. UofL is the only site in Kentucky among 14 nationwide testing the device.

The Zephyr Endobronchial Valve (EBV) is a one-way valve that blocks off diseased lung sections to inhaled air but allows trapped air already inside the area to escape. This enables the collapse of the diseased part of the lung, allowing for the healthier parts of the lung to expand.

Emphysema, a type of chronic obstructive pulmonary disease, is an ongoing, progressive disease of the lower respiratory tract in the lungs. It is a seriously disabling disease with the potential for major complications and is often eventually fatal.

The symptoms of emphysema include shortness of breath and wheezing, an abnormal whistling sound made by the lungs during breathing. It is usually caused by smoking or other long-term exposure to inhaled irritants such as air pollution, chemicals, manufacturing fumes or small particles such as coal dust.

The randomized study, known as the LIBERATE study, is investigating the safety and effectiveness of the EBV for treating emphysema symptoms as compared to a current standard medical therapy program alone. Tanya Wiese, D.O., director of the Interventional Pulmonary Program, is principal investigator of the UofL study.

"The Zephyr EBV's novel mechanism of action shows promise to help the healthy parts of the lung expand and reduce the effect of the disease," Wiese said. "While not a cure, we believe this device could bring relief and improved quality of life to our patients with emphysema."

The EBV can be placed by a doctor in a diseased section of the lungs using bronchoscopy, a procedure to access the lungs using a small tube with a camera on the end. With bronchoscopy, a physician can reach the airways in the lung by passing the tube through either the mouth or nose so invasive surgery is not required.

The problem of emphysema is particularly acute in Kentucky. The American Lung Association estimates that more than 56,000 Kentuckians, or 13 percent of the population, have emphysema, making the incidence of emphysema in Kentucky one of the highest in the United States.

Enrollment in the study is expected to be completed by the end of 2015 and patients will be followed for three years. To schedule an appointment to be screened for inclusion or for more information, contact Crissie DeSpirito at 502-852-0026 or Additional information on the LIBERATE study is available on the national clinical trials website,, using the Clinical Trials Identifier NCT01796392 or by calling 1-888-248-LUNG.

Story Source:

Materials provided by University of Louisville. Note: Content may be edited for style and length.

Cite This Page:

University of Louisville. "Testing investigational device for emphysema." ScienceDaily. ScienceDaily, 27 January 2015. <>.
University of Louisville. (2015, January 27). Testing investigational device for emphysema. ScienceDaily. Retrieved July 23, 2024 from
University of Louisville. "Testing investigational device for emphysema." ScienceDaily. (accessed July 23, 2024).

Explore More

from ScienceDaily